$599

Merck and Dexcom Q3 ’26 Earnings; Ascletis Ph2 T2DM Oral GLP-1RA Data; Oura Ring Obesity Study

A series of cardiometabolic-related news items has been observed from Merck, Ascletis Pharma, Oura, and Dexcom. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here